Humira (adalimumab) / AbbVie, Eisai  >>  Phase 2
Welcome,         Profile    Billing    Logout  

53 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Humira (adalimumab) / AbbVie
NCT00550446 / 2007-002066-35: A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis

Checkmark Data
Feb 2012 - Feb 2012: Data
Completed
2b
386
US, Europe, RoW
Adalimumab, CP-690-550, CP-690,550, Placebo
Pfizer
Arthritis, Rheumatoid
01/09
01/09
NCT01373151 / 2010-023956-99: Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Checkmark EULAR 2014: Rheumatoid Arthritis
May 2014 - May 2014: EULAR 2014: Rheumatoid Arthritis
Checkmark Rheumatoid arthritis - ACR/ ARHP 2013
Sep 2013 - Sep 2013: Rheumatoid arthritis - ACR/ ARHP 2013
Completed
2b
418
Europe, Canada, Japan, US, RoW
BMS-945429 Placebo, BMS-945429, Methotrexate, Methotrexate Placebo, Adalimumab Placebo, Adalimumab
CSL Behring
Rheumatoid Arthritis
09/12
06/15
OSKIRA -4, NCT01264770 / 2010-023692-26: Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Checkmark OSKIRA 4 (EULAR 2013)
May 2013 - May 2013: OSKIRA 4 (EULAR 2013)
Checkmark OSKIRA-4 P2b results
Dec 2012 - Dec 2012: OSKIRA-4 P2b results
Checkmark P2 data (OSKIRA -4)
More
Terminated
2b
644
US, Canada, Europe, RoW
Fostamatinib and placebo injections, Adalimumab and placebo of fostamatinib, Humira®, Placebo of fostamatinib, fostamatinib, and placebo injections
AstraZeneca
Rheumatoid Arthritis
10/12
08/13
OSKIRA 4 SS, NCT02092961: Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study

Terminated
2b
198
US, Canada, Europe, RoW
Fostamatinib, Adalimumab, Placebo of Fostamatinib, Placebo of Adalimumab
AstraZeneca
Rheumatoid Arthritis
07/13
07/13
NCT01752855 / 2012-003881-42: Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab

Completed
2b
88
US, Europe
New formulation adalimumab, Humira
AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
10/13
10/13
NCT00512863: A Dose-Finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects With Refractory Asthma

Withdrawn
2a
272
US
Humira (adalimumab)
Abbott
Asthma
 
 
NCT02097264 / 2013-001492-20: A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Withdrawn
2a
0
Europe
NNC0109-0012, Adalimumab, placebo
Novo Nordisk A/S
Inflammation, Rheumatoid Arthritis
09/15
09/15
NCT00645814: Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed
2
148
US
placebo for adalimumab, placebo, adalimumab, ABT-D2E7, Humira
Abbott
Psoriasis
09/03
 
NCT00646386: Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis

Checkmark EULAR 2014: PsA (ADEPT)
May 2014 - May 2014: EULAR 2014: PsA (ADEPT)
Checkmark ADEPT
Mar 2013 - Mar 2013: ADEPT
Completed
2
315
US
adalimumab, ABT-D2E7, Humira, placebo for adalimumab, placebo
Abbott
Arthritis, Psoriatic
04/04
 
NCT00646191: Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed
2
137
US
adalimumab, ABT-D2E7, Humira
Abbott
Psoriasis
06/04
 
NCT00645892: Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed
2
32
US
adalimumab, ABT-D2E7, Humira, placebo for adalimumab, placebo
Abbott
Psoriasis
09/04
 
NCT00235833: Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

Completed
2
25
Japan
adalimumab, ABT-D2E7, Humira
Abbott, Abbott Japan Co.,Ltd, Eisai Co., Ltd.
Rheumatoid Arthritis
10/04
 
NCT00645905: Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed
2
148
US
adalimumab, ABT-D2E7, Humira, placebo for adalimumab, placebo
Abbott
Psoriasis
03/05
 
NCT00055523: A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease

Completed
2
300
US
Adalimumab (D2E7)
Abbott
Crohn's Disease
 
 
HIDRI2007, NCT00827996: To Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa

Completed
2
10
US
adalimumab
Florida Academic Dermatology Centers, Abbott
Hidradenitis Suppurativa
11/07
08/08
NCT00311246: Trial of Adalimumab in Progressive Sarcoidosis

Terminated
2
11
US
Adalimumab, Humira
University of Chicago, Abbott
Sarcoidosis
05/08
09/08
NCT00298272: Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis

Terminated
2
54
US
IDEC-C2B8 (rituximab), Rituxan, Placebo, Methotrexate, Etanercept, Enbrel, Adalimumab, Humira, Methylprednisolone, Folate
Biogen, Hoffmann-La Roche, Genentech, Inc.
Rheumatoid Arthritis
04/09
07/11
AUGUST II, NCT00595413 / 2007-002536-29: Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis

Completed
2
311
US, Europe
Placebo matched to atacicept, Atacicept: with loading dose, Atacicept, Adalimumab, Humira®
EMD Serono, Merck KGaA, Darmstadt, Germany
Rheumatoid Arthritis
10/09
10/09
NCT00918255 / 2008-004587-38: Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa

Checkmark
Oct 2013 - Oct 2013: 
Completed
2
154
US, Europe
adalimumab, ABT-D2E7, Humira, Placebo
Abbott
Hidradenitis Suppurativa
03/10
11/10
NCT01163617: The Usability and Injection Time of the Physiolis Syringe and Autoinjector in Rheumatoid Arthritis Patients

Completed
2
85
US
Adalimumab delivered in current syringe, ABT-D2E7, Humira, Adalimumab delivered in Physiolis syringe, Adalimumab delivered in current autoinjector, Adalimumab delivered in Physiolis autoinjector
AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
11/10
11/10
NCT00274352: A Study of Adalimumab to Treat Sarcoidosis of the Skin

Completed
2
16
US
adalimumab
Pariser, Robert J., M.D., Abbott, Virginia Clinical Research, Inc.
Sarcoidosis
02/12
02/12
NCT01225393 / 2010-021577-37: A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis

Checkmark EULAR 2013
May 2013 - May 2013: EULAR 2013
Completed
2
211
US, Europe, RoW
MLTA3698A, adalimumab, leflunomide, methotrexate, placebo
Genentech, Inc.
Rheumatoid Arthritis
07/12
 
NCT01502423 / 2011-003953-25: A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab

Completed
2
61
Canada, Europe, RoW
Adalimumab, Humira, ABT-D2E7
AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
11/12
11/12
NCT01561313 / 2011-002275-41: Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab.

Completed
2
64
Europe
Adalimumab, Humira, ABT-D2E7
AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
11/12
11/12
X-PLORE, NCT01483599 / 2011-001066-17: A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis

Checkmark
Feb 2016 - Feb 2016: 
Checkmark BAD 2015
Jul 2015 - Jul 2015: BAD 2015
Checkmark From X-PLORE trial for psoriasis
More
Completed
2
293
US, Canada, Europe
CNTO 1959 (5 mg), CNTO 1959 (15 mg), CNTO 1959 (50 mg), CNTO 1959 (100 mg), CNTO 1959 (200 mg), Adalimumab, Placebo
Janssen Inc.
Psoriasis
11/12
08/13
NCT01712178 / 2012-000535-36: A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety

Completed
2
100
US, Europe
Adalimumab, current formulation, Humira, Adalimumab, new formulation
AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
05/13
05/13
NCT02015793: Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease

Checkmark ECCO-IBD 2015: CD
Jan 2015 - Jan 2015: ECCO-IBD 2015: CD
Completed
2
30
NA
Adalimumab, Placebo for adalimumab
AbbVie
Crohn's Disease
02/15
02/15
NCT02141997 / 2013-004019-37: A Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

Hourglass Nov 2016 - Nov 2016 : In RA at ACR 2016
Completed
2
222
US, Europe, RoW
adalimumab, Humira, ABT-122
AbbVie
Rheumatoid Arthritis
09/15
11/15
NCT02349451 / 2014-003558-15: A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX)

Completed
2
240
NA
adalimumab, Humira, ABT-D2E7, ABT-122, remtolumab
AbbVie
Psoriatic Arthritis
07/16
07/16
NCT01716039: Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)

Terminated
2
22
NA
MTX 12.5, MTX, MTX 25, Adalimumab, Humira
Alimentiv Inc., Abbott
Ulcerative Colitis
07/16
07/16
ADEOS, NCT04154852 / 2008-004877-17: ADalimumab in Persistent Early Oligoarthrits Study

Completed
2
22
Europe
Adalimumab, Methotrexate, Placebo, Folic Acid
University of Leeds, Abbott
Oligoarthritis
01/17
01/17
NCT02833350 / 2016-000335-40: Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)

Completed
2
578
Europe, US, RoW
GDC-0853, RO7010939, Adalimumab, Folic Acid, MTX, Placebo
Genentech, Inc.
Rheumatoid Arthritis
07/18
07/18
NCT03248531 / 2017-000892-10: A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.

Completed
2
90
Europe, US, RoW
Bimekizumab, UCB4940, Adalimumab, Humira®, Placebo
UCB Biopharma SRL
Hidradenitis Suppurativa
11/18
02/19
NCT02983227 / 2016-000498-19: A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350

Checkmark Efficacy data
Jun 2019 - Jun 2020: Efficacy data
Completed
2
496
Europe, US, RoW
GDC-0853, RO7010939
Genentech, Inc.
Rheumatoid Arthritis
07/19
07/19
2017-003249-18: TIGERS study proposes to take mini fragments of synovial tissue to study the molecular patterns present in psoriatic arthritis, in order to to identify markers of disease progression and response to treatment with Ustekinumab, Guselkumab or Adalimumab to analyze and compare different expression patterns within synovial and cutaneous tissue , and to investigate whether molecular diagnosis allows to predict the evolution of the disease in the long term, as well as the therapeutic response.

Completed
2
36
Europe
Ustekinumab, adalimumab, L04AC05, Powder and solvent for solution for injection, Solution for infusion, Solution for injection in pre-filled syringe, Tremfya 100 mg solution for injection in pre-filled syringe., STELARA® 45 mg/0.5 mL or 90 mg/mL solution in a single-dose prefilled syringe, Humira 40 mg solution for injection in pre-filled syringe
Cliniques Universitaires Saint-Luc, Janssen Pharmaceutica
Psoriatic arthritis (PsA), Psoriatic arthritis (PsA) is a type of chronic inflammatory arthritis, Diseases [C] - Immune System Diseases [C20]
 
 
NCT03823391 / 2018-003053-21: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

Completed
2
48
Europe, US, RoW
ABBV-3373, Placebo for ABBV-3373, Adalimumab, Humira, Placebo for adalimumab
AbbVie, Abbvie Inc.
Rheumatoid Arthritis (RA)
04/20
08/20
2018-003053-21: A Clinical Study Testing the Safety, Properties, and Treatment Effects of an Antibody Drug Conjugate ABBV-3373 in Comparison with the Antibody Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis

Not yet recruiting
2
45
Europe
Adalimumab, ABBV-3373, Powder for solution for injection, Solution for injection in pre-filled syringe, Humira (adalimumab)
AbbVie Deutschland GmbH & Co. KG, Abbvie Inc.
Moderate to Severe Rheumatoid Arthritis, The body's immune system attacks the joints, creating inflammation that cause the synovium to thicken. Resulting in swelling and pain in and around the joints. This can cause permanent joint damage., Diseases [C] - Immune System Diseases [C20]
 
 
OKINADA, NCT02471118: Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab

Completed
2
62
Canada
Adalimumab 40 mg, Humira, Placebo
Canadian Research & Education in Arthritis, AbbVie
Osteoarthritis, Knee
03/21
03/21
MARKET, NCT05372939 / 2020-002833-13: Study of the Efficacy and Safety of AMT-101 in Combination With Adalimumab in Subjects With Ulcerative Colitis

Completed
2
51
Europe, RoW
AMT-101 (oral), Placebo (oral), Humira (adalimumab)
Applied Molecular Transport, Applied Molecular Transport Inc.
Ulcerative Colitis
06/22
07/22
2020-002833-13: A study of AMT-101 in combination with Adalimumab in patients with Ulcerative Colitis.

Not yet recruiting
2
50
Europe
AMT-101, Gastro-resistant tablet, Solution for injection in pre-filled pen, Humira
Applied Molecular Transport Inc., Applied Molecular Transport Inc.
Ulcerative Colitis, Ulcerative colitis is a form of inflammatory bowel disease (IBD) that causes inflammation and ulcers in the colon resulting in abdominal pain and bloody diarrhea, Diseases [C] - Digestive System Diseases [C06]
 
 
LYRA, NCT04988308: A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa

Terminated
2
151
Europe, Canada, Japan, US, RoW
Bermekimab, JNJ-77474462, Adalimumab, Placebo
Janssen Research & Development, LLC
Hidradenitis Suppurativa
10/22
11/22
2020-002607-19: A Dose-ranging Study of Bermekimab (JNJ-77474462) in the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa

Completed
2
300
Europe
bermekimab, HUMIRA®, JNJ-77474462, Solution for injection in pre-filled syringe, HUMIRA®
Janssen-Cilag International NV, Janssen Research & Development, LLC
Moderate to Severe Hidradenitis Suppurativa, Acne inversa, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
2021-005947-58: Evaluation of Sonelokimab in Patients with Active Psoriatic Arthritis Zhodnocení přípravku sonelokimab u pacientů s aktivní psoriatickou artritidou

Not yet recruiting
2
200
RoW, Europe
Sonelokimab, adalimumab, Solution for injection in pre-filled syringe, Humira®
MoonLake Immunotherapeutics AG, MoonLake Immunotherapeutics AG
Active Psoriatic Arthritis, Chronic, inflammatory disease of the joints and the places where tendons and ligaments connect to bone., Diseases [C] - Musculoskeletal Diseases [C05]
 
 
M1095-HS-201, NCT05322473 / 2021-005928-38: Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa

Completed
2
234
Europe, Canada, US
Sonelokimab (M1095), Adalimumab, Placebo
MoonLake Immunotherapeutics AG, MoonLake Immunotherapeutics AG
Hidradenitis Suppurativa
05/23
08/23
DUET, NCT04655807 / 2020-002701-26: A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease

Withdrawn
2
0
US
JNJ-64304500, Placebo, Adalimumab, Ustekinumab
Janssen Research & Development, LLC
Crohn Disease
05/23
09/23
2021-005928-38: Evaluation of Sonelokimab for the treatment of patients with active moderate to severe HS

Not yet recruiting
2
210
Europe, RoW
Sonelokimab, adalimumab, Solution for injection in pre-filled syringe, Humira®
MoonLake Immunotherapeutics AG, MoonLake Immunotherapeutics AG
Active moderate to severe hidradenitis suppurativa, Pain due to a skin condition that causes small, painful lumps to form under the skin and scarring on the skin., Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
NCT05640245 / 2021-005947-58: Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

Completed
2
207
Europe, US, RoW
Sonelokimab, M1095, Placebo, Adalimumab
MoonLake Immunotherapeutics AG, MoonLake Immunotherapeutics AG
Arthritis, Psoriatic
09/23
01/24
NCT06242652: A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS)

Active, not recruiting
2
250
RoW
608 Dose A, SSGJ-608 Dose A, 608 Dose B, SSGJ-608 Dose B, 608 Dose C, SSGJ-608 Dose C, Adalimumab, Humira, Placebo
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Ankylosing Spondylitis
02/25
06/25
NCT06257875: A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

Active, not recruiting
2
156
Europe, Canada, Japan, US, RoW
Lutikizumab, ABT-981, Adalimumab, Humira
AbbVie
Ulcerative Colitis
09/27
09/27
STRATIFY, NCT03938701: Fluorescence Imaging of IBD and RA Using Adalimumab-800CW

Recruiting
2
36
Europe
Adalimumab-800CW, Humira, Fluorescence Imaging, Quantified fluorescence molecular endoscopy
University Medical Center Groningen, AbbVie
IBD, Rheumatoid Arthritis
03/26
08/26
NCT07151937: A Study of LAD191 in Adults With Hidradenitis Suppurativa

Not yet recruiting
2
200
NA
LAD191, Placebo, Adalimumab
Almirall, S.A.
Hidradenitis Suppurativa
05/27
11/27
FA-Crohn, NCT01275508: Safety and Tolerability of FITC-Adalimumab Administration During Confocal Laser Endomicroscopy of the Gut

Completed
1/2
25
Europe
FITC-Adalimumab
University of Erlangen-Nürnberg Medical School, Abbott
Crohn's Disease
04/12
04/12
NCT01704599: Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis

Terminated
1/2
8
US
Humira Then Humira plus 3 B vitamins, Humira, Adalimumab, Vitamin B6, Pyridoxine, Vitamin B9, Folic Acid, Vitamin B12, Cyanocobalamin
Wayne State University, Abbott
Psoriasis
06/13
05/14

Download Options